Premium
Management of SARS‐CoV‐2 pneumonia
Author(s) -
Sagnelli Caterina,
Celia Benito,
Monari Caterina,
Cirillo Salvatore,
De Angelis Giulia,
Bianco Andrea,
Coppola Nicola
Publication year - 2021
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.26470
Subject(s) - pneumonia , medicine , coronavirus , immunology , viral pneumonia , virology , virus , disease , intensive care , covid-19 , respiratory disease , public health , intensive care medicine , infectious disease (medical specialty) , lung , pathology
Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection has rapidly spread throughout the world since December 2019 to become a global public health emergency for the elevated deaths and hospitalizations in Intensive Care Units. The severity spectrum of SARS‐CoV‐2 pneumonia ranges from mild to severe clinical conditions. The clinical course of SARS‐CoV‐2 disease is correlated with multiple factors including host characteristics (genetics, immune status, age, and general health), viral load and, above all, the host distribution of the airways and lungs of the viral receptor cells. In this review, we will briefly summarize the current knowledge of the characteristics and management of coronavirus disease 2019‐pneumonia. However, other studies are needed to better understand the pathogenetic mechanisms induced by SARS‐Cov‐2 infection, and to evaluate the long‐term consequences of the virus on the lungs.